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Exogenous gangliosides affect the angiogenic activity of fibroblast growth factor-2 (FGF-2),
but their mechanism of action has not been elucidated. Here, a possible direct interaction of
sialo-glycolipids with FGF-2 has been investigated. Size exclusion chromatography demon-
strates that native, but not heat-denatured, 125I-FGF-2 binds to micelles formed by ganglio-
sides GT1b, GD1b, or GM1. Also, gangliosides protect native FGF-2 from trypsin digestion at
micromolar concentrations, the order of relative potency being GT1b . GD1b . GM1 5 GM2
5 sulfatide . GM3 5 galactosyl-ceramide, whereas asialo-GM1, neuraminic acid, and N-
acetylneuramin-lactose were ineffective. Scatchard plot analysis of the binding data of fluo-
rochrome-labeled GM1 to immobilized FGF-2 indicates that FGF–2/GM1 interaction occurs
with a Kd equal to 6 mM. This interaction is inhibited by the sialic acid-binding peptide
mastoparan and by the synthetic fragments FGF-2(112–129) and, to a lesser extent, FGF-
2(130–155), whereas peptides FGF-2(10–33), FGF-2(39–59), FGF-2(86–96), and the basic
peptide HIV-1 Tat(41–60) were ineffective. These data identify the COOH terminus of FGF-2
as a putative ganglioside-binding region. Exogenous gangliosides inhibit the binding of
125I-FGF-2 to high-affinity tyrosine-kinase FGF-receptors (FGFRs) of endothelial GM 7373
cells at micromolar concentrations. The order of relative potency was GT1b . GD1b . GM1
. sulfatide a 5 sialo-GM1. Accordingly, GT1b,GD1b, GM1, and GM2, but not GM3 and
asialo-GM1, prevent the binding of 125I-FGF-2 to a soluble, recombinant form of extracellular
FGFR-1. Conversely, the soluble receptor and free heparin inhibit the interaction of fluoro-
chrome-labeled GM1 to immobilized FGF-2. In agreement with their FGFR antagonist activ-
ity, free gangliosides inhibit the mitogenic activity exerted by FGF-2 on endothelial cells in
the same range of concentrations. Also in this case, GT1b was the most effective among the
gangliosides tested while asialo-GM1, neuraminic acid, N-acetylneuramin-lactose, galactosyl-
ceramide, and sulfatide were ineffective. In conclusion, the data demonstrate the capacity of
exogenous gangliosides to interact with FGF-2. This interaction involves the COOH terminus
of the FGF-2 molecule and depends on the structure of the oligosaccharide chain and on the
presence of sialic acid residue(s) in the ganglioside molecule. Exogenous gangliosides act as
FGF-2 antagonists when added to endothelial cell cultures. Since gangliosides are extensively
shed by tumor cells and reach elevated levels in the serum of tumor-bearing patients, our
data suggest that exogenous gangliosides may affect endothelial cell function by a direct
interaction with FGF-2, thus modulating tumor neovascularization.
§ Corresponding author. E-mail address: presta@med.unibs.it.
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INTRODUCTION
Gangliosides are neuraminic acid (NeuAc)1-contain-
ing glycosphingolipids. Under physiological condi-
tions, gangliosides are mainly associated to the cell
membranes where they play different roles in control-
ling cell growth, cell adhesion, and cell–cell interac-
tion (Hakomori, 1990; Zeller and Marchase, 1992).
Gangliosides shed in the microenvironment during
tumor growth and metastasis (Merritt et al., 1994;
Chang et al., 1997) possibly as a consequence of their
aberrant overproduction by tumor cells induced by
various cytokines. Indeed, IL-1 (Kjaer et al., 1992),
interferon-g (IFN-g), IL-2, IL-4 (Hoons et al., 1991;
Ando et al., 1996), tumor necrosis factor-a (Furukawa
et al., 1990), PDGF (Pilkington et al., 1993), fibroblast
growth factor-2 (FGF-2), and EGF (Drago et al., 1989)
affect the synthesis and surface expression of different
gangliosides. Conversely, both free and cell-associated
gangliosides can modulate the expression of cyto-
kines. For instance, gangliosides inhibit the produc-
tion of IL-1 b, tumor necrosis factor-a, and IL-6
(Ziegler-Heitbrock et al., 1992; Dumontet et al., 1994)
while GD3 stimulates the production of vascular en-
dothelial growth factor in human glioma cells
(Koochekpour et al., 1996).
Gangliosides modulate the biological activity of
growth factors and cytokines. Exogenous GM1, GM3,
and GT1b inhibit neurite outgrowth induced by PDGF,
insulin, nerve growth factor, and insulin-like growth
factor-1 (Hynds et al., 1997). They also inhibit neuroblas-
toma cell proliferation induced by PDGF (Hynds et al.,
1995; Zhang et al., 1995). GM1 and GM3 affect EGF- and
PDGF-dependent fibroblast proliferation (Bremer et al.,
1986). Moreover, gangliosides modulate IL-2- and IL-3-
dependent proliferation of different cell types of the im-
mune system (Sharom et al., 1991; Nakamura et al., 1996).
Also, GM2 and GT1 are able to modulate the antiviral
activity of human IFN (Besancon and Ankel, 1974; Ven-
gris et al., 1976). Finally, glucosylceramide synthesis has
been demonstrated to be required for FGF-2 to stimulate
axonal growth (Boldin and Futerman, 1997). Accord-
ingly, gangliosides influence FGF-2–dependent mito-
genesis and migration of glial cells (Meuillet et al.,
1996a,b), and GM3 inhibits the proliferation of fibroblasts
exposed to FGF (Bremer and Hakomori,1982).
The mechanisms by which gangliosides modulate
the biological activity of growth factors and cytokines
are not fully elucidated. Experimental evidence indi-
cates that exogenous gangliosides are incorporated
into the plasma membrane and may affect the activity
of tyrosine kinase receptors and intracellular signal-
ing. For instance, membrane-incorporated GM3 inhib-
its ligand-induced autophosphorylation of EGF recep-
tor. This occurs in the absence of a direct interaction of
the ganglioside with the growth factor or modifica-
tions of the binding of EGF to its receptor (Bremer et
al., 1986; Hanai et al., 1988a,b; Weis and Davis, 1990;
Song et al., 1991). Gangliosides inhibit ligand-induced
dimerization and autophosphorylation of PDGF re-
ceptor (Nojiri et al., 1991; Van Brocklyn et al., 1993;
Hynds et al., 1995) and prevent the activation of down-
stream second messengers (Saqr et al., 1995; Sachinidis
et al., 1996). On the other hand, the incorporation of
GM1 and GM3 into the cell membrane of 3T3 fibro-
blasts increases the affinity of PDGF binding in the
absence of a direct interaction with PDGF (Bremer et
al., 1984), whereas exogenous GM1 and GM2 inhibit
PDGF binding to its receptors, suggesting an interac-
tion of free gangliosides with the growth factor
and/or the receptor (Sachinidis et al., 1996). Indeed,
exogenous gangliosides have been shown to bind di-
rectly to IFN (Besancon and Ankel, 1974), IL-2 (Chu
and Sharom, 1990), IL-4 (Chu and Sharom, 1995), and
to the nerve growth factor receptor Trk (Mutoh et al.,
1995). In conclusion, gangliosides play an important
role in regulating the biological activity of growth
factors and cytokines by different mechanisms of ac-
tion. In turn, growth factors regulate the ganglioside
composition of the plasma membranes and of the
extracellular environment.
Angiogenesis is the process of generating new capil-
lary blood vessels. Uncontrolled endothelial cell prolif-
eration is observed in tumor neovascularization. Several
growth factors and cytokines have been shown to stim-
ulate endothelial cell proliferation in vitro and in vivo,
and FGF-2 was one of the first among them to be char-
acterized (Moscatelli et al., 1986). FGF-2 is a Mr 18,000
heparin-binding cationic polypeptide that induces pro-
liferation, migration, and protease production in endo-
thelial cells in culture and neovascularization in vivo
(Basilico and Moscatelli, 1992). FGF-2 interacts with en-
dothelial cells through two distinct classes of receptors,
the high-affinity tyrosine-kinase receptors (FGFRs) and
low-affinity heparan sulfate proteoglycans (HSPGs)
present on the cell surface and in the extracellular matrix
(Jonhson and Williams, 1993). Both classes of receptors
are necessary for the transduction of the signal generated
by the growth factor (Yayon et al., 1991) and for its
internalization inside the cell (Roghani and Moscatelli,
1992; Rusnati et al., 1993).
Gangliosides are highly expressed in the hypervas-
cularized areas of gliomas (Koochekpour and Pilking-
ton, 1996), and they regulate the neovascularization
process in vivo (Ziche et al., 1989, 1992; Gullino et al.,
1990; Cockerill et al., 1995; Gullino, 1995). Interest-
ingly, GM2 and GM3 inhibit FGF-2–mediated endothe-
lial cell proliferation, and the addition of GD3 restores
1 Abbreviations: FGF, fibroblast growth factor; FGFR, tyrosine-
kinase FGF receptor; HSPGs, heparan sulfate proteoglycans;
IFN, interferons; MAE cells, mouse aortic endothelial cells;
NeuAc, neuraminic acid; xcFGFR-1, soluble extracellular form
of FGFR-1/flg. Gangliosides are named according to the nomen-
clature of Svennerholm (1964).
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optimal levels of cell growth (Alessandri et al., 1992;
Ziche et al., 1992). In contrast, GD3 enhances the che-
motactic activity exerted by FGF-2 on endothelial cells,
which is counteracted by GM3 (Ziche et al., 1992).
Moreover, GM1, GD1b, and GT1b act synergistically
with FGF-2 in favoring survival, growth, and motility
of capillary endothelial cells (De Cristian et al., 1990).
Finally, angiogenesis induced by FGF-2 in the rabbit
cornea assay can be stimulated or repressed by mod-
ulating the GM3:GD3 molar ratio (Ziche et al., 1992).
An increase of the angiogenic activity of FGF-2 can
also be obtained by increasing the local concentration
of GM1 and GT1b (Ziche et al., 1989).
Little is known about the mechanism(s) by which gan-
gliosides affect the angiogenic activity of FGF-2 during
tumor growth. The shedding of gangliosides by tumor
cells can be so extensive as to alter the ganglioside com-
position of the extracellular environment of the tumor
and to cause an increase of their serum levels (Kloppel et
al., 1977). Different observations have shown the capacity
of gangliosides to bind directly to certain growth factors
(see above). Moreover, the heparin-binding properties of
FGF-2 and its capacity to interact with various polysul-
fated/polysulfonated compounds point to the possibil-
ity that anionic NeuAc groups of sialo-gangliosides may
mimic sulfated/sulfonated groups of glycosaminogly-
cans in FGF-2 interaction. In the present article we in-
vestigated the capacity of exogenous free gangliosides to
interact directly with FGF-2 and to affect the biological
activity of the growth factor in endothelial cells.
MATERIALS AND METHODS
Chemicals
Human recombinant FGF-2 was expressed and purified from trans-
formed Escherichia coli cells by heparin-Sepharose chromatography
(Isacchi et al., 1991). Recombinant FGF-1 and FGF-4 were gifts from
C. Basilico (New York University Medical Center, New York, NY).
The recombinant, soluble form of the extracellular domain of FGFR-
1/flg (xcFGFR-1) (Bergonzoni et al., 1992) was provided by A. Isac-
chi (Pharmacia-Upjohn, Nerviano, Italy). Synthetic peptides repre-
senting different fragments of human FGF-2 (Schubert et al., 1987)
were kindly donated by A. Baird (Prizm Pharmaceuticals, San
Diego, CA). The synthetic peptide representing the basic domain
of HIV-1 Tat protein was from the Medical Research Council
AIDS Reagent Project (Potters Bar, Herts, United Kingdom). 4,4-Di-
fluoro-5,7-dimethyl-4-bora-3a,4a-diaza-s-indacene-3-dodecanoil acid
(BODIPY-dodecanoil acid) was obtained from Molecular Probes
(Eugene, OR). Gangliosides, N-acetylneuramin-lactose, and masto-
paran were from Sigma (St. Louis, MO). Sulfatide was prepared
from pig brain by the method of Hara and Radin (1979), and its
chromatographic purity and conversion to the sodium salt were
determined as described (Cestaro et al., 1982). Details about the
structure of the gangliosides and ganglioside-related molecules uti-
lized in this study are detailed in Table 1.
Cell Cultures
Transformed fetal bovine aortic endothelial GM 7373 cells were
obtained from the N.I.G.M.S. Human Genetic Mutant Cell Reposi-
tory (Institute for Medical Research, Camden, NJ). They correspond
to the BFA-1c multilayered transformed clone described by Grins-
pan et al. (1983). GM 7373 cells were grown in Eagle’s minimal
essential medium containing 10% FCS, vitamins, and essential and
nonessential amino acids. Spontaneously immortalized BALB/c
mouse aortic endothelial 22106 cells (MAE cells) were grown in
DMEM containing 10% FCS (Bastaki et al., 1996).
125I-FGF-2 Cell Binding and Internalization
FGF-2 was iodinated as described (Neufeld and Gospodarowicz,
1985) at a specific radioactivity equal to 800 cpm/fmol. GM 7373
were incubated at 4°C in serum-free medium containing 10 ng/ml
125I-FGF-2, 0.15% gelatin, 20 mM HEPES buffer (pH 7.5), and the
indicated concentrations of the ganglioside under test. After 2 h, the
amount of 125I-FGF-2 bound to low- and high-affinity binding sites
was evaluated as described (Moscatelli, 1987). Briefly, after a PBS
wash, cells were rinsed twice with 2 M NaCl in 20 mM HEPES
buffer (pH 7.5) to remove 125I-FGF-2 bound to low-affinity binding
sites and twice with 2 M NaCl in 20 mM sodium acetate (pH 4.0) to
remove 125I-FGF-2 bound to high-affinity binding sites. Nonspecific
binding was measured in the presence of a 100-fold molar excess of
unlabeled FGF-2 and subtracted from all the values.
In some experiments, GM 7373 cells were preloaded with GM1
before the 125I-FGF-2 cell-binding assay. To this purpose, cells were
seeded at 70,000 cells/cm2 in 24-well dishes. After 16 h, cells were
incubated for an additional 72 h in fresh medium containing 0.4%
FCS in the absence or in the presence of 100 mM GM1. At the end of
incubation, cells were extensively washed with PBS and incubated
Table 1. Structural characteristics of gangliosides and related compounds utilized in this study
Moleculea Schematic structure
N-Acetylneuramin-lactose NeuAc 23 3Gal 13 4Glc 1
Galactosyl-ceramide 3Gal 13 19Cer
Sulfatide SO323 3Gal 13 19Cer
asialo-GM1 Gal 13 3GalNAc 13 4Gal 13 4Glc 13 19Cer
GM1 Gal 13 3GalNAc 13 4Gal(34 2NeuAc) 13 4Glc 13 19Cer
GM2 GalNAc 13 4Gal(34 2NeuAc) 13 4Glc 13 19Cer
GM3 NeuAc 23 3Gal 13 4Glc 13 19Cer
GD1b Gal 13 3GalNAc 13 4Gal (34 2NeuAc84 2NeuAc) 13 4Glc 13 19Cer
GT1b NeuAc 23 3Gal 13 3GalNAc 13 4Gal(34 2NeuAc84 2NeuAc) 13 4Glc 13 19Cer
Glc, glucose; Gal, galactose; GalNAc, N-acetyl-galactosamine; NeuAc, neuraminic-acid; Cer, ceramide.
a Ganglioside nomenclature according to Svennerholm (1964).
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at 4°C in serum-free medium containing 10 ng of 125I-FGF-2 per ml
in the absence of free ganglioside. After 2 h, the amount of 125I-
FGF-2 bound to low- and high-affinity binding sites was evaluated
as described above. To assess the amount of ganglioside incorpo-
rated during the preloading incubation period, parallel cultures
were trypsinized and cells were sonicated at 50 W for 2 min at 4°C.
Then, samples were centrifuged for 20 min at 40,000 3 g, and the
amount of NeuAc was evaluated in the cell membrane and cytosolic
fractions as described previously (Svennerholm, 1956).
For cell internalization assays, GM 7373 cells were incubated with
125I-FGF-2 exactly as described above. After 2 h, cell cultures were
shifted at 37°C and incubated for an additional 6 or 24 h. At the end
of incubation, surface-bound 125I-FGF-2 was removed as described
above, and cell-internalized 125I-FGF-2 was recovered by lysing the
cells with 0.1 mM Tris-HCl (pH 8.1) containing 0.5% Triton X-100.
Cell Proliferation and DNA Synthesis Assays
Cell proliferation assay on GM 7373 cells was performed as de-
scribed (Presta et al., 1989). Briefly, GM 7373 cells were seeded at
70,000 cells/cm2 in 24-well dishes. Plating efficiency was higher
than 90%. After overnight incubation, cells were incubated for 24 h
in fresh medium containing 0.4% FCS in the absence or in the
presence of 10 ng/ml FGF-2 and the indicated concentrations of
gangliosides. At the end of incubation, cells were trypsinized and
counted in a Burker chamber. For DNA synthesis assay, MAE cells
were seeded at 25,000 cells/cm2 in 24-well dishes and incubated for
2 d with 0.5% FCS. Quiescent cell cultures were then supplemented
with the different mitogens in the absence or in the presence of GT1b
and incubated for 16 h at 37 C°. At the end of incubation, cells were
pulse labeled with [3H]thymidine (1 mCi/ml) for 6 h. The amount of
radioactivity incorporated into the trichloroacetic acid-precipitable
material was then measured.
Size Exclusion Chromatography
To assess the association between FGF-2 and micellar gangliosides,
100-ml samples containing 3 pmol of 125I-FGF-2 were incubated for
10 min at 4°C with 125 nmol of the different gangliosides. Then,
samples were chromatographed on a size-exclusion fast protein
liquid chromatography Superose-12 column (Pharmacia, Piscat-
away, NJ) in PBS with a flow rate equal to 1.0 ml/min. Elution
profiles of FGF-2 and of the ganglioside were obtained by quanti-
fication of the radioactivity and of the NeuAc content of the different
fractions, respectively. Ferritin (Mr 440,000), immunoglobulin G (Mr
150,000), ovalbumin (Mr 45,000), soybean trypsin inhibitor (Mr
20,100), and cytochrome C (Mr 12,000) were chromatographed un-
der the same experimental conditions as molecular size standards.
Proteolytic Digestion and SDS-PAGE
The protective effect of gangliosides on tryptic digestion of FGF-2
was evaluated as described (Coltrini et al., 1993). Briefly, FGF-2
aliquots (55 pmol) were equilibrated at 37°C for 5 min in 50 mM
Tris-HCl (pH 7.5) in the presence of increasing amounts of the
ganglioside under test. Then, 60 ng of trypsin (Sigma, St. Louis, MO)
were added in a final volume of 100 ml, and digestion was allowed
to proceed at 37°C for 3 h. At the end of trypsin digestion, samples
were added with an equal volume of SDS-reducing sample buffer,
boiled at 100°C for 2 min, and subjected to 15% SDS-PAGE. Gels
were stained with the silver staining procedure. The amount of
undigested protein in a given line was estimated by soft-laser scan-
ning of the gel.
Preparation of BODIPY-12-labeled GM1
BODIPY-12-GM1 was synthesized and purified according to previ-
ously described procedures (Marchesini et al., 1994) by acylation of
lyso-GM1 with the N-hydroxy succinimide ester of BODIPY-dode-
canoic acid.
Coating of FGF-2 to Plastic and Binding Assay
Aliquots (100 ml) of 100 mM NaHCO3 (pH 9.6) (carbonate buffer),
containing 20 mg/ml native or heat-denatured FGF-2, were added to
polystyrene nontissue culture microtiter plates. After 16 h of incu-
bation at 4°C, the solution was removed and wells were washed
three times with PBS. Experiments using 125I-FGF-2 as a tracer
revealed that up to 10% of the protein binds to plastic under these
experimental conditions (Rusnati et al., 1997a).
For competition binding assays, the indicated amounts of
BODIPY-12-GM1 were incubated for 10 min at room temperature
into wells coated with 20 mg/ml native or heat-denatured FGF-2 in
the absence or in the presence of the indicated concentrations of
unlabeled GM1, heparin, xcFGFR-1, or synthetic FGF-2 fragments.
At the end of incubation, wells were washed three times with PBS,
and FGF-2-associated GM1 was eluted from the wells with 100 ml of
methanol-chloroform solution (40:60, vol/vol) and measured with a
FCT-150 spectrofluorimeter ( Jasco Spectroscopic, Tokyo, Japan) at
its optimal excitation and emission wavelengths. Nonspecific bind-
ing was measured in wells incubated with carbonate buffer and was
subtracted from all the data.
For the determination of the Kd of the interaction of BODIPY-12-
GM1 with FGF-2, 100-ml aliquots of PBS containing different con-
centrations of labeled GM1 were added into wells coated with 20 mg
of FGF-2 per ml. Then samples were processed exactly as described
above. Nonspecific binding was subtracted from all the data, which
were then analyzed by the Scatchard plot procedure (Scatchard,
1949).
Cross-Linking of 125I-FGF-2 to xcFGFR-1
125I-FGF-2 (0.3 pmol) was incubated in PBS for 2 h at 37°C with 3
pmol of the soluble extracellular form of FGFR-1/flg (xcFGFR-1) in
the absence or in the presence of 1.5 nmol of the ganglioside under
test. At the end of the incubation, the complexes between xcFGFR-1
and 125I-FGF-2 were cross-linked by adding 1 mM bis[2-(succinimi-
doxy-carbonyloxy)ethyl] sulfone (BSOCOES, Pierce Chemical,
Rockford, IL). After 30 min of incubation at room temperature, the
reaction was stopped by the addition of reducing SDS-PAGE sam-
ple buffer. Samples were boiled and analyzed by 10% SDS-PAGE.
Gels were dried and exposed to Kodak X-OMAT AR film (Eastman
Kodak, Rochester, NY) at 270°C for 1 wk.
RESULTS
Size Exclusion Chromatography of
125I-FGF-2–Ganglioside Complexes
Gangliosides form high-molecular-weight micelles
when dissolved in aqueous solutions at concentrations
higher than the critical micellar concentration (which
usually ranges from 1028 to 1025 M) (Formisano et al.,
1979; Ulrich-Bott and Wiegandt, 1984; Saqr et al., 1993).
Accordingly, gel filtration chromatography performed
on a Superose-12 size-exclusion fast protein liquid
chromatography column (Pharmacia) demonstrates
that gangliosides dissolved in PBS at 1.25 3 1023 M
form high-molecular-weight micelles that elute with
the void volume of the column (7 ml) (Figure 1A).
Conversely, low-molecular-weight 125I-FGF-2 (Mr
18,000) elutes with a retention volume equal to 27 ml.
On this basis, to assess a possible interaction of FGF-2
with gangliosides, 3 pmol of 125I-FGF-2 were preincu-
bated for 10 min at room temperature with 125 nmol
of GM1 (final concentration of the ganglioside equal to
1.25 3 1023 M) and then loaded onto the Superose-12
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column. Under these experimental conditions, 125I-
FGF-2 preincubated with GM1 dramatically changes
its chromatographic behavior and coelutes with the
ganglioside in the void volume of the column, thus
indicating the formation of 125I-FGF-2–GM1 complexes
(Figure 1B). Similar results were obtained when 125I-
FGF-2 was preincubated with the same doses of GM2,
GM3, GD1b, or GT1b (our unpublished results),
whereas asialo-GM1 was unable to complex the
growth factor (Figure 1B). Also, no 125I-bFGF–GM1
complexes were observed when the growth factor was
heat denatured before incubation with the ganglioside
(Figure 1B), thus indicating that NeuAc and a correct
three-dimensional structure of FGF-2 are required for
ganglioside interaction.
The capacity of gangliosides to complex with FGF-2
is dose dependent, as shown by the progressive re-
duction of the high-molecular-weight peak corre-
sponding to the 125I-bFGF–GM1 complex paralleled by
the appearance of a retained peak of free 125I-bFGF
when the growth factor was preincubated with de-
creasing doses of GM1 (Figure 1C).
Gangliosides Protect FGF-2 from Trypsin Digestion
Sulfated glycosaminoglycans bind to FGF-2 and pro-
tect it from tryptic digestion (Coltrini et al., 1993). This
capacity has been utilized to study the structural fea-
tures of FGF-2–binding polysulfated/polysulfonated
compounds (Coltrini et al., 1993). On this basis, the
possibility that ganglioside interaction can prevent
FGF-2 proteolysis was investigated. To this purpose,
aliquots of FGF-2 (55 pmol) were equilibrated at 37°C
for 5 min in the presence of increasing amounts of the
different gangliosides. Then, 60 ng of trypsin were
added, and proteolytic digestion was allowed to pro-
ceed at 37°C for 3 h. At the end of incubation, samples
were analyzed by SDS-PAGE followed by silver stain-
ing of the gel (Figure 2A), and the amount of undi-
gested FGF-2 was quantified by soft laser scanning. As
shown in Figure 2, A and B, gangliosides protect
FGF-2 from tryptic digestion in a dose-dependent
manner as a function of the number of NeuAc resi-
dues of the molecule, the order of relative potency of
the gangliosides tested being GT1b . GD1b . GM1. It
should be pointed out that GT1b was unable to protect
heat-denatured FGF-2 from trypsin digestion (Figure
3), thus confirming that the protective effect of gan-
gliosides depends on the interaction with FGF-2, and
not with the proteolytic enzyme, and that this interac-
tion occurs only when the growth factor is present in
the proper native conformation.
The above data suggest that NeuAc residue(s) are of
importance in gangliosides–FGF-2 interaction. Ac-
cordingly, asialo-GM1 does not prevent tryptic diges-
tion of FGF-2 (Figure 2B). In addition, however, free
NeuAc and N-acetylneuramin-lactose, a disaccharide
bearing one NeuAc group, do not protect FGF-2 from
tryptic digestion at doses up to 250 mM (Figure 2C),
thus suggesting that NeuAc residue(s) associated with
defined glycosphingolipidic structures are required
for optimal FGF-2 interaction. Relevant to this point is
the observation that GM3 shows a reduced capacity to
bind and protect FGF-2 from trypsin digestion when
compared with GM2 and GM1 (Figure 2C). Since these
monosialo-gangliosides differ in the length of their
oligosaccharide chain (see Table 1), the data point to
the importance of the saccharide structure in present-
ing NeuAc to FGF-2.
Anionic groups as sulfates can equal the protein-
recognition properties of sialic acids (Rosen and Ber-
tozzi, 1994), and specific sulfated glycolipids have
Figure 1. Size-exclusion chromatography of FGF-2–ganglioside
complexes. (A) 100 ml samples containing 3 pmol of 125I-FGF-2 (F)
or 125 nmol of GM1 () in PBS were incubated for 10 min at room
temperature, loaded separately onto size-exclusion fast protein liq-
uid chromatography Superose-12 column, and eluted in PBS at 1
ml/min flow rate. Radioactivity or NeuAc concentration was mea-
sured in each fraction for the evaluation of 125I-FGF-2 or ganglioside
content, respectively. (B) 3 pmol of native (F, E) or of heat-dena-
tured 125I-FGF-2 () were incubated for 10 min at room temperature
with 125 nmol of GM1 (closed symbols) or of asialo-GM1 (E). Then,
samples were subjected to size-exclusion chromatography as in
panel A, and radioactivity was measured in each fraction. (C) 3
pmol of 125I-FGF-2 were incubated for 10 min at room temperature
with decreasing concentrations of GM1 [12.5 nmol (F), 5 nmol (E),
1.25 nmol (), or 0.125 nmol ()]. Then, samples were subjected to
size-exclusion chromatography as in panel A, and radioactivity was
measured in each fraction. Molecular size standards (in thousands)
were ferritin (Mr 440,000), that eluted with the void volume of the
column (V0), IgG (Mr 150,000), ovalbumin (Mr 45,000), soybean
trypsin inhibitor (Mr 20,100), and cytochrome C (Mr 12,000).
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been demonstrated to bind to hepatocyte growth fac-
tor (Kobayashi et al., 1994). Accordingly, sulfatide was
able to protect FGF-2 from proteolytic cleavage with a
potency similar to GM1 and GM2, whereas galactosyl-
ceramide exerted a limited effect (Figure 2C). Taken
together, the data indicate that NeuAc residue(s), the
oligosaccharide chain, and, to a limited extent, the
ceramide moiety of the ganglioside play a role in
FGF-2 interaction.
FGF-2 belongs to a family of heparin-binding
growth factors (Basilico and Moscatelli, 1992). To as-
sess whether the ganglioside-binding capacity is lim-
ited to FGF-2, trypsin digestion experiments were also
performed with FGF-1 and FGF-4. As shown in Figure
3, all FGFs tested are protected from trypsin digestion
by GT1b, suggesting that various members of the FGF
family share structural features responsible for gangli-
oside interaction.
Gangliosides Bind to Immobilized FGF-2
FGF-2 immobilized onto nontissue culture plastic re-
tains its cell-binding capacity and biological activity
(Presta et al., 1992; Rusnati et al., 1997a). On this basis,
FGF-2 was adsorbed to plastic and evaluated for its
capacity to bind to BODIPY-12-labeled GM1. As
shown in Figure 4A, fluorochrome-labeled GM1 binds
to immobilized FGF-2. The binding was dose depen-
dent and saturable, specificity being demonstrated by
the incapacity of BODIPY-12-GM1 to interact with im-
mobilized heat-denatured FGF-2. Scatchard plot anal-
ysis of the binding data indicates that BODIPY-12-
GM1 binds to immobilized FGF-2 with a Kd equal to
6.3 6 2 mM (Figure 4B). Unlabeled GM1 competed for
the binding of BODIPY-12-GM1 to FGF-2 in a dose-
dependent manner, half-maximal inhibition being ob-
served at equimolar concentrations of the two com-
pounds (Figure 4C). Asialo-GM1 did not exert any
inhibitory effect on the binding of the labeled gangli-
oside to the growth factor. These data demonstrate
that the BODIPY fluorochrome group does not inter-
Figure 2. Protection of FGF-2 from tryptic digestion by ganglio-
sides and related molecules. (A) Representative experiment in
which 1 mg aliquots of FGF-2 were incubated at 37° C for 3 h with
60 ng of trypsin in the absence or in the presence of the indicated
amounts of GM1. Then samples were analyzed by 15% SDS-PAGE
followed by silver staining of the gel. (B and C) Aliquots (1 mg) of
FGF-2 were incubated with trypsin in the presence of the indicated
amounts of asialo-GM1 (E), GM1 (F), GD1b (), GT1b (f) (panel B)
or GM1 (F), NeuAc (M), N-acetylneuramin-lactose (), GM2 (),
GM3 (l), sulfatide (), galactosyl-ceramide (L) (panel C). Then
samples were analyzed by 15% SDS-PAGE followed by silver stain-
ing of the gel. The amount of nondigested FGF-2 was evaluated by
soft-laser scanning of the gel, and data are expressed as percentage
of digested FGF-2 in respect to samples in which trypsin was
omitted. Each point is the mean of two to five determinations in
duplicate. SEM never exceeded 13% of the mean value.
Figure 3. Ganglioside-mediated
protection of FGF-1 and FGF-4
from tryptic digestion. Aliquots
(1 mg) of native or heat-denatured
(h.d.) FGF-2, FGF-1, or FGF-4
were incubated at 37°C for 3 h
with 60 ng of trypsin in the ab-
sence or in the presence of 8 nmol
of GT1b. Then samples were ana-
lyzed by 15% SDS-PAGE fol-
lowed by silver staining of the
gel.
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fere with FGF-2–GM1 interaction. On this basis,
BODIPY-12-GM1 was utilized for further studies.
Gangliosides Interact with the COOH Terminus of
FGF-2
To identify the region(s) of the FGF-2 molecule re-
sponsible for ganglioside interaction, 2.4 nmol of
BODIPY-12-GM1 were incubated for 10 min at room
temperature with equimolar concentrations of syn-
thetic peptides representing different regions of the
FGF-2 molecule (in the present article, amino acid
numbering 1–155 was utilized for FGF-2). Then, the
mixtures were added to FGF-2–coated wells, and the
capacity of the different FGF-2 fragments to prevent
the binding of BODIPY-12-GM1 to the immobilized
growth factor was evaluated. An irrelevant basic pep-
tide, represented by the basic domain (amino acid
residues 41–60) of HIV-1 Tat, a protein able to bind
heparin and other polyanionic compounds (Rusnati et
al., 1997b), and mastoparan, a peptide from wasp
venom that binds to sialic acid residue(s) of ganglio-
sides (Bueb et al., 1990), were used as negative and
positive controls, respectively. Among the FGF-2 pep-
tides tested, only FGF-2(112–129) and, to a lesser ex-
tent, FGF-2(130–155) inhibit the binding of BODIPY-
12-GM1 to immobilized FGF-2 (Figure 5). Accordingly,
two synthetic peptides containing both FGF-2 frag-
ments and corresponding to amino acid sequences
FGF-2(112–155) and FGF-2(116–155) inhibited the
binding of BODIPY-12-GM1 (Figure 5). Under the
same experimental conditions, mastoparan abolished
FGF-2–GM1 interaction while the basic peptide HIV-1
Tat(41–60) was ineffective. Thus, the data implicate
the COOH terminus of the FGF-2 molecule in gangli-
oside interaction.
Gangliosides Inhibit FGF-2 Interaction with
Tyrosine-Kinase FGF Receptor
The above data prompted us to investigate whether
the interaction of free gangliosides with FGF-2 is able
to modulate the ability of the growth factor to bind to
high-affinity tyrosine-kinase FGFRs and/or to low-
affinity HSPGs in endothelial cells. To this purpose,
experimental conditions (i.e., low temperature and
short time of incubation) were adopted to minimize
possible alterations of ligand-receptor interaction due
to ganglioside uptake and incorporation into the cell
membrane (Saqr et al., 1993). On this basis, subconflu-
ent cultures of endothelial GM 7373 cells were incu-
bated at 4°C with 10 ng/ml 125I-FGF-2 in the absence
or in the presence of increasing concentrations of the
different gangliosides. After 2 h, the amount of 125I-
FGF-2 associated with FGFRs and HSPGs was evalu-
ated. As shown in Figure 6A, gangliosides inhibit the
binding of 125I-FGF-2 to FGFR in a dose-dependent
manner. Among the gangliosides tested, GT1b showed
the strongest antagonist activity and fully inhibited
125I-FGF-2 binding to FGFRs at the dose of 30 mM.
GM1 and GD1b showed intermediate inhibitory capac-
Figure 4. Binding of fluorochrome-labeled GM1 to immobilized
FGF-2. (A) Increasing concentrations of BODIPY-12-GM1 were in-
cubated for 5 min at room temperature into wells coated with 20
mg/ml native (F) or heat-denatured (f) FGF-2. At the end of incu-
bation, the BODIPY-12-GM1 bound to the immobilized growth fac-
tor was extracted and measured with a spectrofluorimeter. In panel
B, binding data were analyzed by the Scatchard plot procedure.
They are representative of three independent experiments that gave
similar results. (C) Aliquots (50 ml) containing 1 nmol of BODIPY-
12-GM1 were incubated for 5 min at room temperature into FGF-2-
coated wells in the presence of 100 nmol of asialo-GM1 (M) or of
increasing concentrations of unlabeled GM1 (F). At the end of
incubation, the amount of BODIPY-12-GM1 bound to the immobi-
lized growth factor was extracted, measured, and compared with
the amount of BODIPY-12-GM1 bound to immobilized FGF-2 in the
absence of any competitor. Each point is the mean of two determi-
nations in duplicate. SEM never exceeded 5% of the mean value.
Figure 5. Mapping of the ganglioside-binding region of FGF-2.
Aliquots (50 ml) containing 2.4 nmol of BODIPY-12-GM1 were in-
cubated for 5 min at room temperature into FGF-2–coated wells in
the presence of 2.5 nmol of various synthetic peptides representing
different fragments of FGF-2, of the basic domain of HIV-1-Tat, or of
mastoparan. At the end of incubation, the amount of BODIPY-12-
GM1 bound to the immobilized growth factor was extracted, mea-
sured, and compared with the amount of fluorescent GM1 bound to
immobilized FGF-2 in the absence of any peptide. Each point is the
mean 6 SEM of two to three determinations in duplicate. *, Statis-
tically different from control (p , 0.05).
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ity, whereas asialo-GM1 and sulfatide were the least
effective. At variance with the FGFR binding data, the
gangliosides tested did not inhibit significantly the
binding of 125I-FGF-2 to endothelial HSPGs, a limited
effect being exerted by sulfatide only (Figure 6B). Fi-
nally, free NeuAc did not affect the binding of 125I-
FGF-2 to FGFRs nor to HSPGs, even when tested at
doses as high as 300 mM (our unpublished results).
FGF-2 interaction with the endothelial cell surface
leads to its internalization (Roghani and Moscatelli,
1992; Rusnati et al., 1993). On this basis, we investi-
gated the effect of free gangliosides on FGF-2 internal-
ization in GM 7373 cells. As shown in Figure 6C, GT1b
inhibits both early and late internalization of 125I-
FGF-2 into GM 7373 cells, while the control ganglio-
side asialo-GM1 was ineffective. It must be pointed out
that, because of the contribution of HSPGs to FGF-2
cell entry (Roghani and Moscatelli, 1992; Rusnati et al.,
1993), a limited internalization of FGF-2 occurs also in
the presence of concentrations of GT1b (30 mM) suffi-
cient to cause a complete inhibition of FGF-2 binding
to FGFRs (see Figure 6A).
To rule out the possibility that the observed effects
of gangliosides on FGF-2–FGFR interaction were due
to plasma membrane alterations consequent to a lim-
ited incorporation of the ganglioside during the short-
term binding assay, GM 7373 cells were exposed for
72 h to fresh medium containing 0.4% FCS in the
absence or in the presence of 100 mM GM1. Under
these conditions, gangliosides are efficiently incorpo-
rated into the cell (Saqr et al., 1993). Accordingly, a
significant increase of the content of plasma mem-
brane-associated NeuAc (2.7 vs. 1.2 nmol of NeuAc/
106 cells) and of cytosolic NeuAc (6.0 vs. 4.0 nmol of
NeuAc/106 cells) was observed in GM1-treated cells in
respect to control cells. This corresponds to an incor-
poration into the cells of ;2% of the originally added
exogenous GM1. After loading with the ganglioside,
control and GM1-loaded cells were washed with gan-
glioside-free medium and incubated for 2 h at 4°C
with increasing concentrations of 125I-FGF-2. As
shown in Figure 6D, no significant differences were
observed between control and GM1-loaded cells in the
capacity of 125I-FGF-2 to bind to low-affinity HSPGs
and high-affinity FGFRs. Taken together, the data
demonstrate that exogenous free ganglioside, but not
membrane-incorporated GM1, affects FGF-2–FGFR in-
teraction in intact cells.
The capacity of gangliosides to prevent the binding
of 125I-FGF-2 to cell-associated FGFRs prompted us to
assess their ability to affect FGF-2 interaction with the
extracellular domain of FGFR in a cell-free system. To
this purpose, 0.3 pmol of 125I-FGF-2 was incubated for
2 h at 37°C with 3 pmol of a soluble extracellular form
of FGFR-1/flg (xcFGFR-1) (Bergonzoni et al., 1992) in
the absence or in the presence of 1.5 nmol of the
different gangliosides. At the end of incubation 125I-
FGF-2–xcFGFR-1 complexes were chemically cross-
linked and analyzed by SDS-PAGE followed by auto-
radiography of the gel. GM1, GM2, GD1b, and GT1b,
Figure 6. Effect of exogenous gangliosides on the binding of 125I-
FGF-2 to FGFRs and HSPGs and its internalization in endothelial
cells. (A and B) Subconfluent cultures of GM 7373 cells were incu-
bated for 2 h at 4°C with 10 ng/ml 125I-FGF-2 in the presence of the
indicated concentrations of asialo-GM1(E), GM1 (F), GD1b (), GT1b
(M), and sulfatide (f). At the end of incubation, 125I-FGF-2 bound to
FGFRs (A) and to HSPGs (B) was evaluated as described in MATE-
RIALS AND METHODS and expressed as percentage of the radio-
activity measured in cell cultures incubated in the absence of gan-
glioside. Each point is the mean of three determinations in
duplicate. SEM never exceeded 9% of the mean value. (C) Subcon-
fluent cultures of GM 7373 cells were incubated for 2 h at 4° C with
10 ng/ml 125I-FGF-2 with no addition (open bars) or in the presence
of asialo-GM1 (gray bars) or of GT1b (black bars), both at 30 mM. At
the end of incubation, cell cultures were shifted at 37 °C and
incubated at this temperature for the indicated periods of time. At
the end of incubation, cell surface-associated 125I-FGF-2 was re-
moved, and the amount of internalized 125I-FGF-2 was measured.
The data are representative of two independent experiments in
duplicate. (D) GM 7373 cells were incubated for 72 h at 37°C in the
absence (F, ) or in the presence (E, ) of GM1 (100 mM). At the end
of the incubation, cell cultures were washed extensively and incu-
bated for 2 h at 4° C with increasing concentrations of 125I-FGF-2 in
the absence of free ganglioside. At the end of incubation, 125I-FGF-2
bound to FGFRs (circles) and to HSPGs (triangles) was evaluated as
described in MATERIALS AND METHODS. The data are represen-
tative of four independent experiments in duplicate.
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but not asialo-GM1 and GM3, were able to prevent the
binding of 125I-FGF-2 to xcFGFR-1, as demonstrated
by the lack of appearance on the gel of the Mr 68,000
radiolabeled band corresponding to the 125I-FGF-2–
xcFGFR-1 complex (Figure 7A). Conversely, xcFGFR-1
is able to prevent the binding of 1 nmol of BODIPY-
12-GM1 to immobilized FGF-2 in a dose-dependent
manner, a complete inhibition being observed at ;1
mM (corresponding to 50 pmol of soluble receptor per
sample, Figure 7B). Under the same experimental con-
ditions, free heparin prevents the interaction of
BODIPY-12-GM1 with FGF-2 at ;200 nM (correspond-
ing to 10 pmol per sample, Figure 7B). The fivefold
weaker potency of xcFGFR-1, when compared with
free heparin, in preventing the binding of BODIPY-12-
GM1 to immobilized FGF-2 is in keeping with the
relative affinity of the two molecules for the growth
factor (Kd equal to 5–10 and 1 nM for FGF-2–xcFGFR-1
and FGF-2–heparin interaction, respectively) (Bergon-
zoni et al., 1992; Li and Seddon, 1994).
Gangliosides Affect the Biological Activity of FGF-2
in Endothelial Cells
To assess the biological consequences of FGF-2–gan-
glioside interaction, we evaluated the effects of free
gangliosides onto the mitogenic activity exerted by
FGF-2 on cultured endothelial cells in a short-term cell
proliferation assay (Presta et al., 1989). Confluent cul-
tures of GM 7373 cells were incubated for 24 h with 10
ng/ml FGF-2 in the absence or in the presence of
increasing concentrations of different gangliosides. At
the end of incubation, cells were trypsinized and
counted. As shown in Figure 8, sialo-gangliosides in-
hibit FGF-2 mitogenic activity in a dose-dependent
manner. In contrast, asialo-GM1, sulfatide, and galac-
tosyl-ceramide do not inhibit FGF-2–mediated cell
proliferation, in keeping with their inability to inhibit
FGF-2–FGFR interaction (see Figure 6A). As observed
for FGF-2–ganglioside interaction (see above), the in-
hibitory potency of the various gangliosides depends,
Figure 7. Effect of gangliosides on the binding of FGF-2 to
soluble xcFGFR-1. (A) 125I-FGF-2 (0.3 pmol) was incubated for 2 h
at 37°C with 3 pmol of recombinant, soluble xcFGFR-1 in the
absence (ctrl) or in the presence of 1.5 nmol of the indicated
gangliosides. Then, 125I-FGF-2–xcFGFR-1 complexes were chem-
ically cross-linked with BSOCOES and analyzed by 10% SDS-
PAGE followed by autoradiography of the gel. Arrow points to
the cross-linked Mr 69,000 kDa 125I-FGF-2–xcFGFR-1 complex
(Rusnati et al., 1994), which is abrogated by incubation with a
100-fold excess of unlabeled growth factor (FGF-2). (B) Aliquots
(50 ml) containing 1 nmol of BODIPY-12-GM1 were incubated into
plastic dishes coated with 20 mg/ml FGF-2 in the presence of
increasing concentrations of xcFGFR-1 (F) or of heparin (E). At
the end of incubation, fluorescent GM1 bound to the immobilized
growth factor was extracted, measured with a spectrofluorimeter,
and compared with the amount of fluorescent GM1 bound to
immobilized FGF-2 in the absence of the competitor.
Figure 8. Effect of exogenous gangliosides and related compounds
on the mitogenic activity of FGF-2 in endothelial cells. Subconfluent
cultures of GM 7373 cells were incubated for 24 h at 37°C with 10
ng/ml FGF-2 in the presence of increasing concentrations of asialo-
GM1 (E), GM1 (F), GD1b (), GT1b (M), galactosyl-ceramide (f), or
sulfatide (l) (panel A) or of GM2 (L), GM3 (), NeuAc (M),
N-acetylneuramin-lactose (f) (panel B). At the end of incubation,
cells were trypsinized and counted in a Burker chamber. For the
different experimental conditions, data have been calculated as cell
population doublings during the 24-h incubation period and ex-
pressed as percentage of the mitogenic activity exerted by FGF-2 in
the absence of any competitor (equal to 0.8 cell population dou-
blings, see also Figure 9A). Each point is the mean of two to six
determinations in duplicate. SEM never exceeded 16% of the mean
value.
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at least in part, on the number of NeuAc residues
(GT1b being the most potent inhibitor, Figure 8A), to
the length of the oligosaccharide chain (GM1 being
more potent than GM2 and GM3, Figure 8B), and to the
presence of a ceramide portion (free NeuAc and N-
acetylneuramin-lactose being inactive, Figure 8B). The
inhibitory effect exerted by gangliosides on the mito-
genic activity of FGF-2 appears to be specific and
restricted to the members of the FGF family. Indeed,
10 mM GM1 inhibits the mitogenic activity of FGF-2
and FGF-1 without affecting cell proliferation induced
by the phorbol ester 12-O-tetradecanoyl phorbol 13-
acetate, 1,2-dioctanoyl-sn-glycerol, 10% FCS, EGF, or
insulin (Figure 9). It must be pointed out that the lack
of inhibitory activity of GM1 on FGF-independent
stimuli does not reflect the relative potency of the
mitogen under test, the ganglioside being equally in-
effective when cells were stimulated by a potent in-
ducer (e.g., 10% FCS) or by a much weaker mitogen
(e.g., 1,2-dioctanoyl-sn-glycerol).
The FGF-2-antagonist activity of gangliosides is not
restricted to GM 7373 cells. Indeed, GT1b inhibits DNA
synthesis induced by FGF-2 in MAE cells in culture
(Figure 9B). Also, in this case the inhibitory effect appears
to be specific since GT1b does not affect [3H]thymidine
incorporation stimulated by insulin or 10% FCS.
DISCUSSION
Previous observations had shown that gangliosides
can modulate the biological activity of FGF-2 in vitro
(Bremer and Hakomori, 1982; De Cristian et al., 1990)
and in vivo (Ziche et al., 1989, 1992). Here we demon-
strate that FGF-2 binds to gangliosides in solution.
This interaction is able to prevent the binding of FGF-2
to tyrosine-kinase FGFRs with a consequent inhibition
of the mitogenic activity exerted by the growth factor
on endothelial cells.
FGF-2–ganglioside interaction depends upon de-
fined structural features of both molecules. Binding to
FGF-2 and consequent inhibition of receptor binding
and mitogenic activity of the growth factor occur in
the micromolar range of concentrations of ganglioside,
above its critical micellar concentration (Formisano et
al., 1979; Ulrich-Bott and Wiegandt, 1984). Under these
experimental conditions the oligosaccharide chain of
the glycosphingolipid is exposed to the aqueous envi-
ronment and available for FGF-2 interaction. Several
observations point to the importance of NeuAc resi-
dues of the oligosaccharide chain in this interaction.
Indeed, the relative potency of the ganglioside in pro-
tecting FGF-2 from trypsin digestion, in inhibiting its
interaction with cell surface FGFRs, and in preventing
its mitogenic action appears to be related, at least in
part, to the number of sialic acid residues present on
the glycosphingolipid, GT1b being usually the most
effective. Moreover, the lack of NeuAc groups in the
oligosaccharide chain impairs the capacity of the gan-
glioside to interact with FGF-2, as observed for asialo-
GM1. However, sialic acid alone fails to bind to the
growth factor. Also, the presence of one sialic acid
residue in N-acetylneuramin-lactose is not sufficient to
confer to this molecule the capacity to interact with
FGF-2. Taken together, these data indicate that NeuAc
Figure 9. Effect of GM1 on the mitogenic activity of different
endothelial cell mitogens. (A) Subconfluent cultures of GM 7373
cells were incubated for 24 h at 37°C in 0.4% FCS with no addition
(control) or with FGF-2 (10 ng/ml), FGF-1 (30 ng/ml), EGF (30
ng/ml), insulin (10 mg/ml), 10% FCS, 12-O-tetradecanoyl phorbol
13-acetate (TPA, 30 ng/ml), or 1,2-dioctanoyl-sn-glycerol (DAG, 5
mg/ml) in the absence (white bars) or in the presence (gray bars) of
10 mM GM1. At the end of incubation, cells were trypsinized and
counted in a Burker chamber. Data are expressed as cell population
doublings during the 24-h incubation period. Each point is the
mean 6 SEM of two to six determinations in duplicate. All mitogens
induce a statistically significant increase of cell proliferation rate
(Student’s t test, p , 0.05). (B) MAE cells were incubated for 2 d with
0.5% FCS. Quiescent cell cultures were then treated with vehicle
(0.5% FCS), FGF-2 (30 ng/ml), insulin (10 mg/ml), or 10% FCS in the
absence (white bars) or in the presence of 30 mM (gray bars) or 100
mM (black bars) of GT1b. After 16 h, cells were pulse labeled with
[3H]thymidine (1 mCi/ml) for 6 h. The amount of radioactivity
incorporated into the trichloroacetic acid-precipitable material was
measured. Each point is the mean 6 SEM of three determinations in
triplicate. At both concentrations, GT1b causes a statistically signif-
icant decrease of DNA synthesis induced by FGF-2 (Student’s t test,
p , 0.05).
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must be presented to FGF-2 in the contest of a defined
glycolipidic structure to exert its FGF-2 binding capacity.
In N-acetylneuramin-lactose, which is unable to
bind FGF-2, NeuAc is linked to a short glucose-galac-
tose disaccharide. This structure is comparable to that
of the oligosaccharide chain of GM3 (see Table 1) that,
among the monosialo-gangliosides tested, has the
shortest oligosaccharide chain and the poorest FGF-2
antagonist activity. This suggests that the length and
structure of the oligosaccharide chain are also of im-
portance in determining the FGF-2-binding activity of
the ganglioside. The lack of FGF-2–binding activity of
N-acetylneuramin-lactose, when compared with GM3,
may also suggest that the ceramide portion of the
ganglioside is involved in FGF-2 interaction, as sup-
ported by the observation that galactosyl-ceramide
protects FGF-2 from trypsin digestion with a potency
similar to that of GM3. Taken together, the results
indicate that FGF-2–ganglioside interaction occurs via
NeuAc residue(s) and is strictly regulated by other
components of the glycolipidic structure. Similar con-
clusions have been drawn from sialic acid recognition
studies of selectins to sialylated Lewis blood group
epitopes (McEver et al., 1995). Also in this case, selectin
interaction depends not only on the presence and
structure of the sialic acid residue but also on that of
other saccharide residues (i.e., fucose and galactose) in
the oligosaccharide chain.
Sulfation of sialyl Lewis X is of importance for se-
lectin interaction (Rosen and Bertozzi, 1994), and an-
ionic groups as sulfates can equal the protein-recogni-
tion properties of sialic acids, as shown by the capacity
of L- and P-selectins to bind to sulfatides and subsets
of heparin fragments (Rosen and Bertozzi, 1994). Ac-
cordingly, our data demonstrate that sulfatide can
bind FGF-2 and protect it from proteolytic cleavage
with a potency similar to mono-sialo gangliosides.
These observations are of particular relevance when
the heparin-binding properties of FGF-2 and its capac-
ity to interact with various polysulfated/polysulfon-
ated compounds are considered (Coltrini et al., 1993).
On this basis, the possibility that negatively charged
NeuAc groups might interact with the strongly cat-
ionic FGF-2 molecule could be anticipated. However,
our observations indicate that the binding of sialo-
gangliosides to FGF-2 is not the consequence of a mere
electrostatic interaction but depends upon specific
structural features of the growth factor. Indeed, FGF-2
must be present in a proper three-dimensional confor-
mation to interact with gangliosides. Also, a ganglio-
side-binding region has been identified in the COOH
terminus of the FGF-2 molecule by synthetic peptide-
binding experiments. Peptide FGF-2(112–129) and to a
lesser extent peptide FGF-2(130–155), as well as pep-
tides FGF-2(112–155) and FGF-2(116–155), were able
to prevent the binding of BODIPY-12-GM1 to the im-
mobilized growth factor, whereas peptides FGF-2(10–
34), FGF-2(39–59), and FGF-2(82–96) were ineffective
(note that in the present work amino acid numbering
1–155 has been used for FGF-2). The specificity of
these observations is confirmed by the inability of the
highly charged basic peptide HIV-1 Tat(41–60) to bind
GM1 under the same experimental conditions.
Peptide FGF-2(112–129) and larger FGF-2 fragments
containing this amino acid sequence had been shown
to bind heparin and to prevent the binding of FGF-2 to
its high-affinity FGFRs, suggesting that this region
(formerly known as the putative receptor-binding
loop) is involved in receptor recognition and binding
(Baird et al., 1988). More recent observations, based on
site-directed mutagenesis of the FGF-2 molecule, x-ray
crystallography data, isothermal titrating calorimetry,
and computer modeling, have indicated that two sep-
arate receptor-binding sites adjacent to a discontinu-
ous heparin-binding domain exist in FGF-2 (Panto-
liano et al., 1994; Springer et al., 1994; Thompson et al.,
1994). This allows the formation of heparin–FGF-2–
FGFR ternary complexes (Pantoliano et al., 1994). The
primary, high-affinity receptor-binding site is com-
prised of six discontinuous residues that are located
on the same face of the FGF-2 molecule. The second,
low-affinity receptor-binding site is a surface-exposed
type I b-turn within the putative receptor-binding
loop and is composed of residues FGF-2(120–124).
This region is required for receptor dimerization in
vitro, and mitogenic signal transduction in cultured
cells (Springer et al., 1994). We have observed that
gangliosides hamper the capacity of 125I-FGF-2 to
complex in solution with the recombinant form of
xcFGFR-1 and prevent its interaction with FGFRs
present on the endothelial cell surface. However, none
of the gangliosides tested prevent the binding of 125I-
FGF-2 to GM 7373 cell surface HSPGs, even though
this interaction occurs with a much lower affinity than
FGF-2–FGFR interaction (Kd equal to 300 and 20 pM
for the two interactions, respectively). The higher
abundance of cell-surface HSPGs in respect to FGFRs
(4.4 3 105 vs. 1.6 3 104 binding sites/cell, respectively)
may explain this apparent discrepancy (Rusnati et al.,
1993). Indeed, under appropriate experimental condi-
tions, both heparin and soluble xcFGFR-1 can prevent
the binding of fluorochrome-labeled GM1 to immobi-
lized FGF-2 (see Figure 7B). Thus, gangliosides bind to
COOH-terminal region(s) of FGF-2 overlapping or ad-
jacent to those involved in heparin–heparan sulfate
and FGFR interactions.
These observations raise the possibility that exoge-
nous gangliosides may exert a FGF-2 antagonist activ-
ity by a direct interaction with the growth factor, thus
preventing its binding to tyrosine-kinase FGFRs. This
hypothesis is supported by experimental evidence in-
dicating that the structural features of the ganglioside
required to bind FGF-2 and protect it from trypsin
digestion are similar to those required to prevent
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FGFR binding and mitogenic activity. Moreover, both
GM 7373 cells and MAE cells proliferate when ex-
posed to different tyrosine-kinase- and protein kinase
C-dependent mitogens, including phorbol ester, dia-
cyl-glycerol, serum, EGF, or insulin, in the presence of
concentrations of ganglioside sufficient to inhibit the
mitogenic activity exerted by FGF-2. This demon-
strates that the inhibitory activity exerted by ganglio-
sides is specific for FGF-2 and is not the consequence
of a general impairment of the capacity of endothelial
cells to respond to mitogenic stimuli. Interestingly,
gangliosides are also able to inhibit the mitogenic
activity of FGF-1, another member of the FGF family
that shares with FGF-2 various structural and biolog-
ical features, including FGFR- and HSPG-binding ca-
pacity (Jonhson and Williams, 1993). These findings,
together with the observation that FGF-1, FGF-2, and
FGF-4 are protected from trypsin digestion by GT1b,
suggest that different members of the FGF family
share structural features responsible for ganglioside
interaction.
As stated above, sulfatide binds FGF-2 and protects
it from proteolytic cleavage. Nevertheless, free sul-
fatide is unable to prevent FGF-2–FGFR interaction
and to inhibit FGF-2–mediated cell proliferation.
These observations indicate that the capacity of a mol-
ecule to interact with FGF-2 in vitro does not neces-
sarily reflect its FGF-2 antagonist potential. Similar
conclusions had been drawn for FGF-2–binding hep-
arin derivatives (Ishihara et al., 1993; Coltrini et al.,
1994). For instance, N-desulfated/N-acetylated beef
lung heparin is as potent as unmodified heparin in
preventing the proteolytic digestion of FGF-2, but it is
highly inefficient in inhibiting the receptor-binding
and mitogenic activity of the growth factor (Coltrini et
al., 1994). Thus, the capacity of a molecule to bind
FGF-2 in a cell-free system and to modulate its biolog-
ical activity can be dissociated at the structural level.
This appears to be of importance for the development
of synthetic FGF-2 inhibitors.
Here we have shown that a short-term incubation of
GM 7373 cells with FGF-2 in the presence of free
gangliosides causes an inhibition of the receptor-bind-
ing and mitogenic activity of the growth factor. In
apparent contrast with these observations, De Cristian
et al. (1990) demonstrated that a 6-h preincubation of
endothelial cells with GT1b followed by a further 72-h
incubation in the presence of both GT1b and FGF-2
increases the mitogenic activity of the growth factor.
The addition of exogenous gangliosides to cell cul-
tures is a widely used approach to investigate their
effects on cell behavior. However, the diversified con-
ditions under which they are added to cultured cells
cause different degrees of ganglioside incorporation
into cell membrane, making comparison among ex-
periments difficult (Saqr et al., 1993). Conflicting re-
sults may therefore depend on the free or cell-associ-
ated status of the ganglioside and reflect different
mechanisms of action of these glycolipids. Our data
demonstrate that free gangliosides present in their
micellar form in the cell culture medium bind and
sequester FGF-2, preventing its interaction with cell-
surface FGFRs. In contrast, cell membrane-incorpo-
rated glycolipids may regulate the biological activity
of FGF-2 in the absence of free gangliosides by differ-
ent mechanisms of action, possibly by affecting the
activity of tyrosine kinase receptors and intracellular
signaling, as already demonstrated for various growth
factors, including PDGF and EGF (see INTRODUC-
TION). Accordingly, we have observed that a 72-h
incubation of GM 7373 cells with GM1 leads to a
significant incorporation of the glycolipid into the cell
membrane. Even though this does not result in a sig-
nificant modification of the capacity of the cells to bind
FGF-2 (see above), GM1 preloaded cells proliferate
more efficiently than control cells in response to FGF-2
with a consequent 10-fold increase of the potency of
the growth factor (ED50 equal to 1.0 and 10 ng/ml
FGF-2 for GM1 preloaded and control cells, respec-
tively) (Rusnati and Urbinati, unpublished data). In
agreement with this hypothesis is the observation that
membrane-associated gangliosides modulate the bio-
logical activity of FGF-2 in fibroblasts and glial cells in
the absence of a direct interaction with the growth
factor (Bremer and Hakomori, 1982; Meuillet et al.,
1996a,b), probably by regulating tyrosine autophos-
phorylation of FGFR (Meuillet et al., 1996a,b).
Taken together, the data suggest that exogenous free
gangliosides and membrane-incorporated glycolipids
can modulate the activity of FGF-2 by different mech-
anisms of action. It is interesting to note that soluble
and cell-associated sulfated glycosaminoglycans have
also been demonstrated to play contrasting roles in
modulating the biological activity of FGF-2 (Rusnati
and Presta, 1996). As observed for exogenous ganglio-
sides, soluble glycosaminoglycans protect FGF-2 from
proteolytic cleavage and inhibit FGF-2–FGFR interac-
tion and FGF-2–dependent cell proliferation (Coltrini
et al., 1994; Rusnati et al., 1994). In contrast, cell-asso-
ciated HSPGs increase the local concentration of
FGF-2 and modulate FGFR binding, dimerization, and
signaling, thus promoting the biological activity of the
growth factor (Rusnati and Presta, 1996).
In conclusion, we have demonstrated that exoge-
nous free gangliosides 1) protect FGF-2 from proteo-
lytic degradation; 2) modulate the binding of the
growth factor to tyrosine kinase FGFRs; 3) modulate
cell internalization of FGF-2; and 4) inhibit FGF-2–
dependent endothelial cell proliferation. All these ef-
fects occur at concentrations of free ganglioside be-
tween 0.3 and 30 mM. During tumor growth and
metastasis, gangliosides shed in the microenviron-
ment (Kloppel et al., 1977; Merritt et al., 1994; Chang et
al., 1997). This process can be so extensive as to alter
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the ganglioside composition of the extracellular envi-
ronment of the tumor (Kloppel et al., 1977). It has been
demonstrated that tumor cells can shed up to 0.5% of
their membrane ganglioside content per hour (Li and
Ladish, 1991) and that gangliosides are present at
concentrations as high as 10 mM in the serum of tu-
mor-bearing patients (Valentino and Ladisch, 1992).
On this basis, because of the possible role of FGF-2 in
tumor angiogenesis (Rak and Kerbel, 1997), ganglio-
sides shed by tumor cells may affect endothelial cell
function by interacting with FGF-2, thus modulating
tumor neovascularization.
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